The typhoid fever vaccine market is valued at $200 million per year.  Existing commercial typhoid fever vaccines have clear limitations.

Pneumococcal Vaccine Candidate MVX01

Pneumococcal Protective Protein Antigen vaccine candidate - our universal approach to combat pneumococcal disease.

C. difficile Vaccine Candidate MVX02

C. difficile infections results in 14,000 deaths per year in the United States. Matrivax is targeting the pathogen and the toxoids.


Vaccines targeting high-impact bacterial diseases

1. WHO, 2014; 2. WHO, 2000; 3. WHO, 2005; 4. CDC, 2013

Contact Us

650 Albany Street, Suite 117, Boston, MA 02118 

inquiry@matrivax.com  |  Tel: 617-358-7640

© 2019 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118

Tel: 617-3587640